Lemaitre Vascular (LMAT) Director Jasinski Receives Equity Awards

What Happened

• Lawrence J. Jasinski, a director of Lemaitre Vascular (LMAT), was credited with a total of 4.744 dividend-equivalent rights on September 3, 2026. These were recorded as derivative awards (code A) at $0.00 per share (total reported value $0). This is not a cash purchase or sale but the accrual/settlement of dividend equivalents tied to previously granted restricted stock units (RSUs) and performance share units (PSUs).

Key Details

• Transaction date: 2026-09-03; Form 4 filed: 2026-09-08 (filed 5 days after the transaction; Form 4s are typically due within two business days, so this appears late).
• Items credited: 0.543, 0.65, 0.885, 1.002 and 1.664 shares — total 4.744 shares; reported price: $0.00; total value reported: $0.
• Footnotes: Each amount represents a dividend equivalent right that accrued on prior awards and vests proportionately with the underlying award:
  • F1/F3/F5: accrued on RSUs granted 12/8/2023, 12/6/2024, and 12/10/2025 respectively.
  • F2/F4: accrued on PSUs granted 12/8/2023 and 12/6/2024 respectively.
  • Each dividend equivalent right is the economic equivalent of one share of common stock.
• Shares owned after transaction: not specified in the provided filing summary.
• Nature of transaction: derivative award accrual/settlement (not a market purchase or sale).

Context

• Dividend-equivalent rights are payments (in shares here) that mirror dividends on underlying unvested awards; they vest proportionately with the RSUs/PSUs. Because these are accruals on existing awards, they do not reflect an open-market purchase (a stronger bullish signal) or a sale. Retail investors should treat this as routine compensation accounting rather than a direct insider bet on the stock. The late filing reduces transparency and may have regulatory implications.